Bipolar depression study scrapped before it began
NCT ID NCT05060549
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to explore how cariprazine (Vraylar) might help people with bipolar depression by looking at its effect on a specific brain receptor (D3 dopamine). Participants would have taken cariprazine for six weeks and undergone PET scans to see how the drug works in the brain. However, the study was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cariprazine (Vraylar)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Decoding depression: sleep rhythms as biomarkers?
- Can a single psychedelic dose rewire the depressed brain?
- Brain wave clues: could inflammation markers forecast ECT outcomes?
- Can brain implants read and treat bipolar depression without triggering mania?
- Can a 10-Hour eating window stabilize mood in bipolar disorder?
- Brain wave patterns and inflammation: a clue to ECT's effectiveness in older adults?